Loading
companiesCompany
iOnctura
iOnctura is a Switzerland-based biotechnology company running 2 late-stage cancer trials of roginolisib in non-small-cell lung cancer, uveal melanoma and melanoma.
Overview
iOnctura, based in Geneva, Switzerland, is a biotechnology company. iOnctura is a biotech company developing precision oral small-molecule drugs that target the tumour-stroma-immune interface in neglected and hard-to-treat cancers. On ClinicalTrials.gov it is the lead sponsor of 2 recruiting or active phase 2 and phase 3 interventional cancer trials, testing roginolisib in non-small-cell lung cancer, uveal melanoma and melanoma. The largest, NCT06717126 (A Randomised Phase II Study of Roginolisib in Patients With Advanced/Metastatic Uveal Melanoma), plans to enrol 85 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.
Headquarters
Geneva, CH
Scorecard
All companies#443of 1244 companies, score 7
- phase 1/2 +1
- modalities +2
- registry trials +4
0 approved, 0 in phase 3, 1 earlier, 0 targets, 5 registry studies. Formula on the scorecards page.
Type
Stage
Growth stage
Website
Founded
2017
Phase 2Oral PI3K inhibitor
Roginolisib is an oral pi3k inhibitor from iOnctura, in registered phase 2 trials for non-small-cell lung cancer, small-cell lung cancer.
Similar pages
- JournalMelanoma research
Shares Uveal melanoma, Melanoma.
- JournalPigment cell & melanoma research
Shares Uveal melanoma, Melanoma.
- TrialA Study to Investigate the Safety and Efficacy of IOV-3001 in Adults With Advanced Melanoma Who Will Receive Lifileucel
Shares Uveal melanoma, Melanoma.
- Trial(Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma
Shares Uveal melanoma, Melanoma.
- TrialA Study of APG-115 in as a Monotherapy or Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors
Shares Uveal melanoma, Melanoma.
- TrialA Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult P
Shares Uveal melanoma, Melanoma.
- TrialA Phase 1 and 2 Study of VMD-102 in Hepatocellular Carcinoma and Other Solid Tumors
Shares Uveal melanoma, Non-small-cell lung cancer.
- TargetMBD4
Shares Uveal melanoma, Melanoma.
cancers
drugs
Phase 2Oral PI3K inhibitor